Literature DB >> 6187081

Plasma fibrinopeptide A and beta-thromboglobulin in major bacterial infections.

H van Hulsteijn, W Fibbe, R Bertina, E Briët.   

Abstract

The purpose of this study was to assess the usefulness of plasma fibrinopeptide A and beta-thromboglobulin concentrations for the diagnosis of acute venous thromboembolism in patients with a major bacterial infection. In 80 controls the mean plasma fibrinopeptide A concentration was 0.72 +/- 0.47 (ng/ml +/- SD) and the mean plasma beta-thromboglobulin concentration 28.2 +/- 10.1 (ng/ml +/- SD). On admission the mean fibrinopeptide A concentration was significantly raised (5.42 ng/ml) in these patients and 17 of them had a raised fibrinopeptide A concentration. However, the mean beta-thromboglobulin concentration was not significantly different from that of the healthy individuals (35.4 ng/ml) and only three patients had an increased beta-thromboglobulin concentration. Our data show that patients with major bacterial infections tend to have increased fibrinopeptide A and normal beta-thromboglobulin concentrations. Consequently, the measuring of plasma fibrinopeptide A concentration is useless for the diagnosis of acute venous thromboembolism in these patients. However, the determination of plasma beta-thromboglobulin concentration can still be used for this purpose, since a normal beta-thromboglobulin concentration excludes the presence of acute venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6187081

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery.

Authors:  V Abbasciano; F Levato; G Zavagli
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

2.  Endogenous plasma Peptide detection and identification in the rat by a combination of fractionation methods and mass spectrometry.

Authors:  Fabrice Bertile; Flavie Robert; Véronique Delval-Dubois; Sarah Sanglier; Christine Schaeffer; Alain Van Dorsselaer
Journal:  Biomark Insights       Date:  2007-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.